Enhancing Pharmaceutical Quality & Innovation: Highlights from the National Conference 2024

On July 16, 2024, the National Conference on Enhancing Pharmaceutical Quality Assurance & Technology Upgradation brought together industry experts, policymakers, and pharma leaders. Hosted by the PHD Chamber of Commerce & Industry, and supported by the Department of Pharmaceuticals, the conference focused on implementing GMP (Good Manufacturing Practices) and the Revamped Pharmaceutical Technology Upgradation Assistance Scheme (RPTUAS). This marked a significant moment, especially for Neuro Pharma PCD Companies in Punjab, pushing boundaries for innovation, compliance, and global readiness.

Key Panel Discussion and Esteemed Speakers

Moderated by our team, the discussion panel included some of the brightest minds from India’s pharma ecosystem:

Shri Poorvesh Pancholi – GM, Quality, Glenmark Pharma
Shri Munish Thakur – Gen. Secretary, Himachal Drug Manufacturing Association
Dr. Manish Kapoor – State Drug Controller, Baddi, HP
Shri Ravender Singh Dahiya – MD, Mondove Biotech Pvt Ltd & Mediclove Biotech Pvt Ltd

These industry leaders dissected the quality and legal aspects of manufacturing, new Schedule M compliance, and how small to mid-sized pharma units can upgrade technology and ensure better product integrity.

Emphasis on Good Manufacturing Practices (GMP)

GMP is the backbone of quality assurance in the pharma sector. As India evolves as a global manufacturing hub, aligning with GMP frameworks is essential. Discussions covered:

Revised guidelines under Schedule M
Reducing compliance gaps in SMEs
Training programs for internal QA/QC teams
Empowering Neuropsychiatry PCD Pharma Franchise Companies with quality insights

Spotlight on RPTUAS – Revamping Pharma Tech

The Revamped Pharmaceutical Technology Upgradation Assistance Scheme (RPTUAS) is set to revolutionize pharma manufacturing. With capital support and easier access to technology:

Small and medium neuro-pharma PCD franchise in India can modernize plants
Focus will shift to AI-enabled quality checks, IoT-based tracking, and zero-defect production
MSMEs can now scale with government-backed innovation

This opens massive opportunities for companies in Baddi, Telangana, Mohali, and Tamil Nadu, especially for Neuropsychiatry PCD companies in India.

Why This Conference Matters for the Neuro PCD Segment

For companies in the neuro and psychiatric pharma niche, like those focusing on: Anti-depressants Cognitive enhancers Mood stabilizers CNS drugs regulatory compliance, and quality infrastructure are non-negotiable. Companies that adapt now will lead the market later , particularly in high-growth regions like Punjab, Himachal, and Telangana.